Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vical Joins Forces With Astellas On CMV Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.

You may also be interested in...

Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma

CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.

Cash-Strong Vical Narrows Focus To Two Lead Programs

Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts